‘Loneliness pandemic’: Work from home during COVID-19 takes mental toll on Canadians
“Working from home for many people in our society is a risk for further alienation and feeling very lonely and distant,” said Dr. Roger McIntyre”
VeraCity: The Psychedelic Frontier
VeraCity: The Psychedelic Frontier aired January 25 on Citytv. Dr. McIntyre speaks about research and treatments.
Challenges of parenting during the pandemic
Dr. Roger McIntyre on the challenges of parenting during COVID
A phone call may be all it takes to ease pandemic loneliness: study
TORONTO -- Give your friends and family a call, it may just ease the pandemic loneliness, depression and anxiety that are taking hold. A study published in the peer-reviewed journal JAMA Psychiatry suggests that phone calls can help people who are left feeling alone and isolated during the pandemic, no training required. This isn’t overly surprising, for humans have a basic need to connect with others, said Roger McIntyre, a psychiatry and pharmacology professor at the University of Toronto. “It speaks to the fact that as people, as human beings, we need to have contact. That is an undeniable fact. It’s in our DNA, years of evolution. We’re social organisms, we need contact,” McIntyre told CTVNews.ca in a phone interview on Wednesday. The study aimed to quickly address the issue of loneliness during the pandemic and focused on socially isolated adults who...
This is your brain on pandemic: What chronic stress is doing to us
Back in the 1980s, there was a public service announcement on TV that you may remember — or may have seen on YouTube. A guy in a kitchen held up an egg and said, "This is your brain." Then he cracked the egg into a hot frying pan, and said, "This is your brain on drugs." One year into this pandemic, your brain might be feeling a bit like that egg: Fried. "Everything is so much harder," said Stephanie Johnson, a client relationship executive who lives in Toronto. "I don't have the motivation that I used to have. I don't have the efficiency that I used to have." "Defeated" is how Vas Smountas, a freelance graphic designer, describes it. Also living in Toronto, she describes herself these days as "tired, defeated, foggy, unmotivated." And research suggests those feelings are not uncommon right now,...
Pandemic Parenting: Experts on Helping Children Get Past Their Germ Fear
TORONTO -- A year ago, many Canadians were washing down any package that came to the door. Now we’re tearing with abandon into that Amazon box before the masked delivery driver has even left the front porch. But for some, a year’s worth of timed handwashing and pushing crosswalk buttons with our elbows has caused significant stress that won’t be so easy to cast aside when the world turns back to normal. This is particularly true for children who are prone to anxiety. “Certainly (the pandemic) is causing significant distress in kids,” says Dr. Sandra Mendlowitz, a psychologist and co-founder of Reframe Psychology Clinic in Toronto, which focuses on anxiety disorders, depression and obsessive-compulsive disorder (OCD) in children. “Part of being a child is to have lots of social interactions and learn from that, so I think that it's kind...
BRAXIA SCIENTIFIC LAUNCHES PSILOCYBIN-ASSISTED CLINICAL THERAPY TRAINING PROGRAM
BRAXIA SCIENTIFIC LAUNCHES PSILOCYBIN-ASSISTED CLINICAL THERAPY TRAINING PROGRAM TO DEVELOP NEW GENERATION OF QUALIFIED PHYSICIANS, PSYCHOTHERAPISTS AND PSYCHOLOGISTS FOR MENTAL HEALTH TORONTO, ONTARIO June 29, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce it has launched its psilocybin-assisted clinical therapy training program. Through this program, Braxia will develop, train and support a new generation of qualified, skilled in best practices independent medical physicians, psychologists and psychotherapists to implement safe and effective psilocybin-assisted therapy for patients with depression. The therapists will participate in the provision of psychotherapy in upcoming clinical trials at Braxia evaluating the safety and efficacy of psilocybin in depression. The Company anticipates that, pending regulatory approval of psilocybin, therapists would also be...
TRAINING PROGRAM ENROLLMENT FOR SEPTEMBER 2021
Braxia Institute Psilocybin-Assisted Therapy Training Program Request for Applications for Class of 2022 Application Deadline: July 11, 2021 Tentative Program Start Date: September 2021 (pandemic permitting) A total of 14 qualified therapists will be selected for the training program. The training program will include didactic teaching, peer teaching, group discussion and simulations followed by a practicum component. The practicum component will include administering psilocybin-assisted therapy for participants with depression as part of a Health Canada approved clinical trial. We hope to recruit an interdisciplinary group of physicians, psychologists and psychotherapists. Therapists will work in dyads, pairing physician therapists with non-physician therapists as at least one physician is required for all psilocybin doses administered. You will receive group peer-supervision throughout the program. The goal of the course is to become fully competent to perform psilocybin-assisted therapy for future clinical trials and possibly clinical...
ENROLLMENT FOR SEPTEMBER 2021
BRAXIA INSTITUTE TRAINING PROGRAM ENROLLMENT FOR SEPTEMBER 2021 Braxia Institute Psilocybin-Assisted Therapy Training Program Request for Applications for Class of 2022 A total of 14 qualified therapists will be selected for the training program. The training program will include didactic teaching, peer teaching, group discussion and simulations followed by a practicum component. The practicum component will include administering psilocybin-assisted therapy for participants with depression as part of a Health Canada approved clinical trial. We hope to recruit an interdisciplinary group of physicians, psychologists and psychotherapists. Therapists will work in dyads, pairing physician therapists with non-physician therapists as at least one physician is required for all psilocybin doses administered. You will receive group peer-supervision throughout the program. The goal of the course is to become fully competent to perform psilocybin-assisted therapy for future clinical trials and possibly clinical care, if psilocybin...
WEBCAST ALERT: H.C. WAINWRIGHT & CO.
WEBCAST ALERT: H.C. WAINWRIGHT VIRTUAL CONFERENCE PRESENTATION WEBCAST ALERT Dr. Roger McIntyre @ H.C. Wainwright Virtual Conference Presentation The Patient Experience and Commercial Considerations When Launching Psychoactive Agents in Psychiatry Tune in Live on Thursday, 6/17 at 2:00 PM (Eastern Standard Time) Webcast link is closed. Symbols – CSE: BRAX OTC: BRAXF FWB: 496
PSYCHEDELICS IN PSYCHIATRY AND BEYOND
BRAXIA SCIENTIFIC TO PRESENT AT THE PSYCHEDELICS IN PSYCHIATRY AND BEYOND VIRTUAL CONFERENCE HOSTED BY H.C. WAINWRIGHT & CO. ON JUNE 17, 2021 TORONTO, ONTARIO June 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Psychedelics in Psychiatry and Beyond Virtual Conference, hosted by H.C. Wainwright & Co. on June 17, 2021. Braxia’s CEO, Dr. Roger McIntyre will present and participate in a panel discussion, “Patient Experience And Commercial Considerations When Launching Psychoactive Agents In Psychiatry.” Dr. McIntyre will also be available to host virtual one-on-one meetings with institutional investors registered with H.C. Wainwright and Co. For additional information on the conference please visit: https://hcwevents.com/psychedelics/ About Braxia Scientific Corp. Braxia Scientific is a...
KETAMINE AND ESKETAMINE TREATMENT GUIDANCE
AMERICAN JOURNAL OF PSYCHIATRY PUBLISHES INTERNATIONAL KETAMINE AND ESKETAMINE TREATMENT GUIDANCE LED BY BRAXIA SCIENTIFIC CEO DR. ROGER MCINTYRE International Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for the clinical implementation of these rapid-acting treatments in treatment resistant depression Guidance published in the official Journal of the American Psychiatric Association establishes Braxia Scientific as an international leader in the rapidly evolving industry of Ketamine, Esketamine and rapid acting antidepressants TORONTO, ONTARIO June 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the American Journal of Psychiatry, the most widely read psychiatric journal in the world, has published the International Expert Opinion and Implementation Guidance (the “Guidelines”) for the clinical use of...
DR. DAVID GREENBERG TO BOARD OF DIRECTORS
BRAXIA SCIENTIFIC APPOINTS DR. DAVID GREENBERG TO BOARD OF DIRECTORS TORONTO, ONTARIO May 31, 2021 – Braxia Scientific Corp. (the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce it has appointed Dr. David Greenberg to its Board of Directors. A nationally recognized general medical practitioner for more than 30 years and a lecturer at The University of Toronto in the Department of Family and Community Medicine, Dr. David Greenberg brings extensive experience in Mental Health and Concussions. He has developed and implemented multiple education programs for medical practitioners, nationally and internationally, and is regarded as an international health expert and keynote speaker on the topic of depression and related disorders. Dr. Greenberg is the Team Physician for the Toronto Argonauts,...
The Current with Matt Galloway
Understanding pandemic burnout; why tackling deforestation could be key to stopping future viral outbreaks; Yukon enacts comprehensive transgender health care; and Canadian universities battling COVID-19 outbreaks Feeling tired? Unmotivated? You might be experiencing pandemic burnout. We discuss the impact of long-term stress on our brains and memory with Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, and Dr. Natasha Rajah, professor in the department of psychiatry at McGill University and the Douglas Research Centre in Montreal. Then, as this pandemic drags on, scientists are already looking at how to prevent the next one — and some say a key factor will be tackling deforestation. We discuss why with Dr. Jonathan Epstein, a veterinarian and disease ecologist; Kimberly Fornace, an epidemiologist at the London School of Hygiene and Tropical Medicine; and Terry Sunderland, a professor of...
THE BRAXIA INSTITUTE
BRAXIA SCIENTIFIC INTRODUCES THE BRAXIA INSTITUTE Over 200 physicians and healthcare providers from Canada, U.S., and Asia to attend Braxia’s Symposium on rapid acting anti-depressants (RAAD) which include ketamine, esketamine and psychedelic therapies Braxia Institute aims to turn research into clinical action to achieve better outcomes for people with mental illness by closing the extraordinary gap between clinical practice and neuroscience research of ketamine and psychedelic treatment TORONTO, ONTARIO May 20, 2021 – Braxia Scientific Corp. (“Braxia Scientific” or the “Company”), (CSE: BRAX) (FWB: 496) (OTC: SHRMF), a research driven clinical platform developing and providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the launch of the Braxia Institute (“Braxia Institute”), the Company’s training Centre of Excellence focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy for people with...
SYMBOL CHANGE ON OTC MARKETS TO “BRAXF"
BRAXIA SCIENTIFIC ANNOUNCES SYMBOL CHANGE ON OTC MARKETS TO “BRAXF” In Quebec, ~20% of the population, or 1 in 5 people, experience mental illness during their lifetime; Covid-19 has further exacerbated the number of adults experiencing symptoms of major depression This joint venture creates first privately owned clinic in Quebec to address unmet need for accessible, high-quality, advanced mental health services and treatments for depression, suicide, and other mental health disorders including providing access to rapid-onset treatments such as Intravenous ketamine Established in 2006, Neurotherapy Montreal provides access to large network of physicians across Quebec, including +1,200 psychiatrists Neurotherapy Montreal’s large, established patient base includes patients diagnosed with brain-based injuries such as Anxiety, Depression, Attention Deficit Hyperactivity Disorder (ADHD), Traumatic Brain Injury, Stroke, Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, Chronic Pain, Vestibular and Sleep Disorder The Braxia clinic is situated...
FIRST KETAMINE THERAPY CLINIC IN QUEBEC
In Quebec, ~20% of the population, or 1 in 5 people, experience mental illness during their lifetime; Covid-19 has further exacerbated the number of adults experiencing symptoms of major depression This joint venture creates first privately owned clinic in Quebec to address unmet need for accessible, high-quality, advanced mental health services and treatments for depression, suicide, and other mental health disorders including providing access to rapid-onset treatments such as Intravenous ketamine Established in 2006, Neurotherapy Montreal provides access to large network of physicians across Quebec, including +1,200 psychiatrists Neurotherapy Montreal’s large, established patient base includes patients diagnosed with brain-based injuries such as Anxiety, Depression, Attention Deficit Hyperactivity Disorder (ADHD), Traumatic Brain Injury, Stroke, Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, Chronic Pain, Vestibular and Sleep Disorder The Braxia clinic is situated within a 14,000 square foot multi-disciplinary state of the art...
BRAXIA SCIENTIFIC INTRODUCES “BRAXIA HEALTH”
BRAXIA SCIENTIFIC INTRODUCES “BRAXIA HEALTH” A GROWING NETWORK OF CLINICS LEADING NOVEL PSYCHEDELIC RESEARCH AND TREATMENTS FOR MENTAL DISORDERS Braxia Scientific enters a new chapter as it commences trading under its new ticker “CSE: BRAX” and rebrands its growing network of leading clinics to Braxia Health, which includes the Canadian Rapid Treatment Centre of Excellence established in 2018. Only clinic in Canada previously involved in a randomized controlled pivotal trial for regulatory approval purposes of psilocybin for the treatment of adults with depression. Led by Dr. Roger McIntyre, the top-rated expert in depression since 2010 as rated by Expertscape, Braxia Health has the largest clinical research footprint for ketamine and psychedelic-based research in the world, providing the fastest route to development of its IP capable formulations and IP capable delivery methods. First community-based centre in Canada to specialize in rapid-acting treatments...
COMMENTS ON PROSPECTIVE CLASS PROCEEDING
BRAXIA SCIENTIFIC CORP. COMMENTS ON PROSPECTIVE CLASS PROCEEDING TORONTO, ONTARIO May 3, 2021 – Braxia Scientific Corp. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), (formerly Champignon Brands Inc.) announces that it was served with a notice of civil claim in a proposed class proceeding in British Columbia against the Company, its CEO, certain of its former officers, a shareholder, and underwriters which were engaged in connection with a private placement financing for the Company in June 2020. The Company has accepted service as of today’s date. The claim is based on allegations relating to the Company’s disclosure documents regarding the value of four acquisitions made by the Company in 2020 and related matters. The plaintiff is seeking an unspecified amount of damages for the proposed class. The Company intends to vigorously defend the claim. About Braxia Scientific Corp. Braxia...
CHANGES NAME TO BRAXIA SCIENTIFIC CORP
CHAMPIGNON BRANDS CHANGES NAME TO BRAXIA SCIENTIFIC TO REFLECT THE INTEGRATION OF KETAMINE AND PSYCHEDELIC CLINICS AND ITS RESEARCH AND DEVELOPMENT PRIORITIES TORONTO, ONTARIO May 3, 2021 – Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), is pleased to announce that it has changed its name from “Champignon Brands Inc.” to “Braxia Scientific Corp.” and its ticker symbol will change from “SHRM” to “BRAX” on the Canadian Securities Exchange (the “CSE”). The name change reflects the Company’s commitment to providing access to, and leadership in, setting the standard of care for ketamine treatment in depression through its network of clinics, as well as the Company’s ketamine and psychedelic derivative research and drug development priorities. Braxia Scientific’s overarching aim is to shape the future of treatment for people suffering from depression and other mental health disorders. “Our new...
REVOCATION OF CEASE TRADE ORDERS
TORONTO, ONTARIO April 22, 2021 - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), is pleased to announce that the British Columbia Securities Commission and Ontario Securities Commission (the “Commissions”) have revoked their cease trade orders against the Company effective April 22, 2021.
CHAMPIGNON BRANDS ANNOUNCES FILING OF LISTING STATEMENT
TORONTO, ONTARIO, March 26, 2021 /CNW Telbec/ - Champignon Brands Inc. (the "Company"), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announced today that it has filed a new Listing Statement with the Canadian Securities Exchange ("CSE") which contains disclosure regarding the acquisition of AltMed Capital Corp. (“AltMed”) (the “Transaction”). The Transaction constituted a reverse takeover of Champignon by AltMed.
RESTATES FINANCIAL STATEMENTS AND MD&A LISTING
VANCOUVER, BRITISH COLUMBIA – March 11, 2021 - Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announced that as a result of a review by the British Columbia Securities Commission (the “Commission”), the Company has refiled its condensed interim consolidated financial statements and management’s discussion & analysis (“MD&A”) for the three and six month periods ended March 31, 2020 (the “Restated Financial Statements and MD&A”).
CSE LISTING STATEMENT
VANCOUVER, BRITISH COLUMBIA – February 17, 2021 - Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announced that as a result of a review by the British Columbia Securities Commission (the “Commission”), the Company has determined to withdraw and refile its condensed interim consolidated financial statements and management’s discussion & analysis (“MD&A”) for the three and six month periods ended March 31, 2020 (the “Original Financial Statements and MD&A”).